Pasithea Therapeutics recently raised $24 million at its initial public offering (“IPO”). The Company’s Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the...
"I believe that we are on the verge of curing, as opposed to simply treating, certain psychiatric maladies." Dr. Jeffrey Kamlet, Chief Medical Officer of Ehave.
The KCSA Psychedelics Conference features live presentations and speakers who will address the various investment opportunities in psychedelic treatments for mental health disorders.
Psychedelic Stock Review Initiates Coverage on Ehave Inc.
MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics...
MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it...
NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/
VANCOUVER, BC, Sept. 23, 2021 /CNW/ - Delic Holdings Corp. ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0)...
Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr....
Institutional Analyst Inc. announced the release of the 2021 Psychedelic Investor Guide on Monday, October 18th. The Psychedelic Investor Guide is the...
